CapVest's Curium shelves potential $3bn sale amid market volatility

As the JPM and Rothschild process for the French nuclear medicine company is put on hold, attention shifts to Webster Equity-backed PharmaLogic, sources told PE Hub.

17 March 2020•2 mins read
nuclear medicine
LinkedInXEmail
LinkedInXEmail

Related articles